【Sawai Group Holdings】Notice of Dividend Receipt from a Consolidated Subsidiary | May 22, 2026

Performance Overview

Sawai Group Holdings is scheduled to receive a dividend of 832 million yen from its consolidated subsidiary Sawai Pharmaceutical. The dividend will be received on July 31, 2026, and is expected to be recorded as Receipt of Dividends from Affiliates in operating revenue in the individual financial statements for the fiscal year ending March 2027. However, it will not impact the consolidated results. This dividend receipt is positioned as a stable income source from a subsidiary and contributes to financial soundness and improved capital efficiency.

Impact on Shareholders and Future Outlook

This dividend receipt does not directly affect dividends or shareholder returns, but it strengthens the company’s financial base as stable income from a subsidiary. Going forward, the company will continue to monitor subsidiary performance and dividend policies, aiming to maintain financial health and enhance capital efficiency. For investors, securing stable dividend income from affiliated companies is seen as contributing to corporate value improvement.